Coronavirus immunity could 'last for years,' new study suggests

An encouraging new study conducted by several leading labs, including the La Jolla Institute of Immunology, found that most people who have recovered from a coronavirus infection within the last eight months likely have enough immune cells to fight off serious reinfections, The New York Times reports.
While it's still unclear exactly how long immunity may last, or whether it could prevent transmission (though that is certainly plausible), the new study has eased experts' concerns of short-lived protection based on studies that pointed to declining antibodies. Antibodies, after all, are just one facet of the body's complex immune system, and the new study indicated that other factors like T cells showed only a slight decay several months out from infection, while B cells, which produce new antibodies as needed, had actually grown in number in most participants.
The new findings, the Times notes, appear to line up with another recent discovery that survivors of SARS, which was also caused by a coronavirus, still carry important immune cells 17 years after infection. And while there have been cases of reinfection, they seem to be rare, per the Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
More studies will be required to back up the not-yet-peer-reviewed findings, but it's not "unreasonable to think that these immune memory components would last for years," Deepta Bhattacharya, an immunologist at the University of Arizona told the Times. It may also be another layer of good news on the vaccine front, since vaccinations typically provide better, longer-lasting protection than natural infections. If that holds true in the case of COVID-19, people would theoretically get to avoid an annual booster shot. Read more at The New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Mountains of garbage are creating more hazards in Gaza
under the radar Gaza was already creating 1,700 tons of waste daily prior to the war
By Justin Klawans, The Week US Published
-
Crossword: March 3, 2025
The Week's daily crossword
By The Week Staff Published
-
Sudoku medium: March 3, 2025
The Week's daily medium sudoku puzzle
By The Week Staff Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published